Analysis of response rate with ANTI PD1/PD-L1 monoclonal antibodies in advanced solid tumors: a meta-analysis of randomized clinical trials

Abstract

BackgroundAnti-PD1/PD-L1 monoclonal antibodies (mAbs) increase overall survival compared to standard of care (SOC) in different tumors. However, a proportion of patients (pts) will have progressive disease (PD) as best response. We conducted a meta-analysis to study the rates of response comparing these antibodies with SOC.MethodsA search of published trials in MEDLINE and EMBASE analyzing anti-PD1/PD-L1mAbs monotherapy compared to SOC. Relative risk (RR) with 95% confidence interval (CI) of response rates between groups was estimated. Subgroup analyses for location of primary tumor, number of previous treatment lines, selected population by PD-L1 expression and type of radiological assessment were made.ResultsTwelve studies accounting for 6,700 pts were included (anti-PD1/PD-L1 mAbs: 3,451 pts; SOC: 3,249 pts [2,823 pts: chemotherapy, 426 pts: targeted therapy]). Adjusted response rates were (N, %): Complete Response (CR) (69/3153, 2.19%), Partial Response (PR) (596/3153, 18.90%), Stable Disease (SD) (632/2463, 25.66%) and PD (1027/2463, 41.70%); and CR (16/2955, 0.54%), PR (263/2955, 8.90%), SD (835/2269, 36.80%) and PD (834/2269, 36.76%) with anti-PD1/PD-L1 mAbs and SOC, respectively. Anti-PD1/PD-L1 mAbs improved CR rate (RR 3.48) and PR rate (RR 2.27). There were no differences in the PD rate between groups (RR 1.10). Subgroup analyses showed an improvement in clinical benefit with anti-PD1/PD-L1 mAbs for melanoma (RR 1.59; 1.37–1.84 95% CI) and those treated in the first line setting (RR 1.57; 1.27–1.95 95% CI).ConclusionsAnti-PD1/PD-L1 mAbs increase overall response rate compared to SOC without an increase in PD rate. Melanoma and pts treated in first line setting seem to have greater benefit with anti-PD1/PD-L1 mAbs.FindingsIn this systematic meta-analysis, anti-PD1/PD-L1 mAbs were associated with a greater overall response rate. Patients with melanoma and those managed in the first line setting seem to have an additional benefit with anti-PD1/PD-L1 mAbs.

Programmed death-ligand 1 expression and its correlation with clinicopathological parameters in gallbladder cancer

“…Immune checkpoint inhibitors targeting the PD-1-PD-L1 pathway have exhibited potent efficacy in some cancers such as triple-negative breast cancer, renal cell carcinoma, and non-small cell lung cancer [16][17][18][19][20]. Clinical benefits were strongly correlated with high PD-L1 expression and certain drugs have been approved for use in conjunction [20,21].…”

The Immuno-Modulatory Effects of Inhibitor of Apoptosis Protein Antagonists in Cancer Immunotherapy

“…Immunotherapy has had some remarkable successes in the clinic, however the benefit is limited to only a subset of patients. For example, checkpoint blockade therapy, such as α-PD-1 treatment, results in a partial or complete clinical response rate in only~20% of patients with solid tumours [74]. The application of chimeric antigen receptor (CAR) T cell therapy has also been limited to haematological malignancies, largely due to poor CAR T cell infiltration and the hostile tumour microenvironment associated with solid tumours.…”

A Transcriptomic Meta-Analysis Identifies Differentially Expressed Genes across Different Types of Cancer and Their Association with Checkpoint Inhibitor Immunotherapy

“…Additional advantages of this immunotherapy come from the reduced toxicity and lack of immune suppression accompanied by chemo and radiation therapy (5). Yet, despite the simplicity, the elegant approach, and the high success rate of this immunotherapy in treating cancer patients, the approach exhibited a response rate that varied widely among different types of cancers (6).…”